US 12,268,714 B2
Transplantation of mitochondria into lymphoid organ and composition therefor
Masashi Suganuma, Aichi (JP); Hideyoshi Harashima, Hokkaido (JP); Yuma Yamada, Hokkaido (JP); Daisuke Sasaki, Hokkaido (JP); and Takafumi Yokota, Osaka (JP)
Assigned to LUCA Science Inc., Chuo-ku (JP)
Appl. No. 17/275,983
Filed by LUCA Science Inc., Chuo-ku (JP)
PCT Filed Sep. 13, 2019, PCT No. PCT/JP2019/036011
§ 371(c)(1), (2) Date Mar. 12, 2021,
PCT Pub. No. WO2020/054829, PCT Pub. Date Mar. 19, 2020.
Claims priority of provisional application 62/824,668, filed on Mar. 27, 2019.
Claims priority of provisional application 62/731,731, filed on Sep. 14, 2018.
Prior Publication US 2022/0031743 A1, Feb. 3, 2022
Int. Cl. A61K 35/15 (2015.01); A61K 35/17 (2015.01); A61K 35/34 (2015.01)
CPC A61K 35/15 (2013.01) [A61K 35/17 (2013.01); A61K 35/34 (2013.01)] 6 Claims
 
1. A method, comprising: intra-thymically administering to a subject in need thereof a pharmaceutical formulation comprising mitochondria encapsulated within cells, wherein the cells are selected from the group consisting of a cardiac stem cell and a cardiac progenitor cell,
wherein the cells have been treated with a mitochondrial activator prior to the intra-thymical administration,
whereby the cells transfer their mitochondria to mature cells originally present in the thymic tissue.